Clinical registration study of cardiac amyloidosis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024764

Enrollment

Unknown

Registered

2019-07-26

Start date

2019-07-15

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac amyloidosis

Interventions

case series:None

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Biopsy confirmed amyloidosis by pathology; 2. Clinical or imaging suggests that there may be cardiac involvement: (1) Decreased activity tolerance: heart fatigue after exercise, both lower extremity edema; (2) NT-proBNP >=332 ng/L; (3) ECG prompts low voltage; (4) Echocardiography Display: left atrial enlargement, diastolic dysfunction.

Exclusion criteria

Exclusion criteria: The patient refused to participate or was unable to complete the follow-up.

Design outcomes

Primary

Measure	Time frame
New onset arrhythmias, re-hospitalization of heart failure, cardiogenic death, all-cause death;Ventricular volume, function, strain, extracellular volume measured by cardiac magnetic resonance and echocardiography, electrocardiogram, radionuclide imaging to evaluate organ involvement, pro-BNP, blood routine biochemical examination, etc.;	—

Countries

China

Contacts

Public ContactChen Yucheng

West China Hospital of Sichuan University

chenyucheng2003@163.com+86 189 8060 2149

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026